Human pituitary tumor-transforming gene 1 overexpression reinforces oncogene-induced senescence through CXCR2/p21 signaling in breast cancer cells

Breast Cancer Research

Volumn 14, Issue 4, 2012, Pages

  Ruan, Jhen Wei ^a   Liao, Yi Chu ^a   Lua, Ingrid ^a   Li, Ming Hsun ^b   Hsu, Chih Yi ^c   Chen, Ji Hshiung ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; PROTEIN P21; SECURIN; LIGAND; PITUITARY TUMOR-TRANSFORMING PROTEIN 1, HUMAN; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER CELL; CARCINOGENICITY; CELL STRAIN MCF 7; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; ONCOGENE; ORTHOTOPIC TRANSPLANTATION; SCID MOUSE; SENESCENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; BREAST TUMOR; CELL AGING; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; PHENOTYPE; TUMOR CELL LINE; TUMOR INVASION;

BREAST NEOPLASMS; CELL AGING; CELL LINE, TUMOR; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHENOTYPE; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTORS, INTERLEUKIN-8B; SECURIN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863679909     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3226     Document Type: Article

References (62)

1. Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1997, 11:433-441. 10.1210/me.11.4.433, 9092795.
2. Hornig NC, Knowles PP, McDonald NQ, Uhlmann F. The dual mechanism of separase regulation by securin. Curr Biol 2002, 12:973-982. 10.1016/S0960-9822(02)00847-3, 12123570.
3. Zou H, McGarry TJ, Bernal T, Kirschner MW. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999, 285:418-422. 10.1126/science.285.5426.418, 10411507.
4. Genkai N, Homma J, Sano M, Tanaka R, Yamanaka R. Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. Oncol Rep 2006, 15:1569-1574.
5. Fujii T, Nomoto S, Koshikawa K, Yatabe Y, Teshigawara O, Mori T, Inoue S, Takeda S, Nakao A. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology 2006, 43:1267-1275. 10.1002/hep.21181, 16628605.
6. Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 2007, 28:165-186.
7. Zhu X, Mao Z, Na Y, Guo Y, Wang X, Xin D. Significance of pituitary tumor transforming gene 1 (PTTG1) in prostate cancer. Anticancer Res 2006, 26:1253-1259.
8. Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G, Chanson P. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 2006, 65:536-543.
9. Talvinen K, Tuikkala J, Nevalainen O, Rantanen A, Hirsimaki P, Sundstrom J, Kronqvist P. Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer. Br J Cancer 2008, 99:335-340. 10.1038/sj.bjc.6604475, 2480969, 18594525.
10. Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M. PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast 2004, 13:80-81. 10.1016/j.breast.2003.09.008, 14759723.
11. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003, 33:49-54. 10.1038/ng1060, 12469122.
12. Ito T, Shimada Y, Kan T, David S, Cheng Y, Mori Y, Agarwal R, Paun B, Jin Z, Olaru A, Hamilton JP, Yang J, Abraham JM, Meltzer SJ, Sato F. Pituitary tumor-transforming 1 increases cell motility and promotes lymph node metastasis in esophageal squamous cell carcinoma. Cancer Res 2008, 68:3214-3224. 10.1158/0008-5472.CAN-07-3043, 2988648, 18451147.
13. Liao YC, Ruan JW, Lua I, Li MH, Chen WL, Wang JR, Kao RH, Chen JH. Overexpressed hPTTG1 promotes breast cancer cell invasion and metastasis by regulating GEF-H1/RhoA signalling. Oncogene 2012, 31:3086-3097. 3381367, 22002306.
14. Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocr Rel Cancer 2008, 15:721-743.
15. Smith VE, Franklyn JA, McCabe CJ. Pituitary tumor-transforming gene and its binding factor in endocrine cancer. Expert Rev Mol Med 2010, 12:e38.
16. Chesnokova V, Melmed S. Pituitary senescence: the evolving role of PTTG. Mol Cell Endocrinol 2010, 326:55-59. 10.1016/j.mce.2010.02.012, 2906651, 20153804.
17. Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S, Melmed S. p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci USA 2008, 105:17498-17503. 10.1073/pnas.0804810105, 2577704, 18981426.
18. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, Kovacs K, Wawrowsky K, Melmed S. Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res 2007, 67:10564-10572. 10.1158/0008-5472.CAN-07-0974, 2770267, 17975001.
19. Hsu YH, Liao LJ, Yu CH, Chiang CP, Jhan JR, Chang LC, Chen YJ, Lou PJ, Lin JJ. Overexpression of the pituitary tumor transforming gene induces p53-dependent senescence through activating DNA damage response pathway in normal human fibroblasts. J Biol Chem 2010, 285:22630-22638. 10.1074/jbc.M109.096255, 2903424, 20452981.
20. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007, 8:729-740.
21. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011, 11:503-511. 10.1038/nrc3057, 21701512.
22. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol 2011, 192:547-556. 10.1083/jcb.201009094, 3044123, 21321098.
23. Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, Zangari J, Bille K, Robert C, Bressac-de Paillerets B, Hofman P, Rocchi S, Peyron JF, Lacour JP, Ballotti R, Bertolotto C. Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev 2011, 25:1245-1261. 10.1101/gad.625811, 3127427, 21646373.
24. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008, 133:1019-1031. 10.1016/j.cell.2008.03.039, 18555778.
25. Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da Costa M, Brown C, Popov N, Takatsu Y, Melamed J, d'Adda di Fagagna F, Bernard D, Hernando E, Gil J. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008, 133:1006-1018. 10.1016/j.cell.2008.03.038, 18555777.
26. Kuilman T, Peeper DS. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 2009, 9:81-94. 10.1038/nrc2560, 19132009.
27. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007, 7:79-94. 10.1038/nrc2069, 17251915.
28. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-6741. 10.1158/1078-0432.CCR-07-4843, 18980965.
29. Acosta JC, Gil J. A role for CXCR2 in senescence, but what about in cancer?. Cancer Res 2009, 69:2167-2170. 10.1158/0008-5472.CAN-08-3772, 19276354.
30. TRC Lentiviral production. , http://rnai.genmed.sinica.edu.tw/webContent/web/protocols
31. Chan CH, Lee SW, Li CF, Wang J, Yang WL, Wu CY, Wu J, Nakayama KI, Kang HY, Huang HY, Hung MC, Pandolfi PP, Lin HK. Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nat Cell Biol 2010, 12:457-467. 10.1038/ncb2047, 20383141.
32. Mu YM, Oba K, Yanase T, Ito T, Ashida K, Goto K, Morinaga H, Ikuyama S, Takayanagi R, Nawata H. Human pituitary tumor transforming gene (hPTTG) inhibits human lung cancer A549 cell growth through activation of p21(WAF1/CIP1). Endocr J 2003, 50:771-781. 10.1507/endocrj.50.771, 14709851.
33. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011, 12:715-723.
34. Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden JE, Premsrirut P, Luo W, Chicas A, Lee CS, Kogan SC, Lowe SW. Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev 2011, 25:2125-2136. 10.1101/gad.17276711, 3205583, 21979375.
35. Kunsch C, Rosen CA. NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol 1993, 13:6137-6146. 364673, 8413215.
36. Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J Leukocyte Biol 2002, 72:9-18. 2668262, 12101257.
37. Kazhdan I, Marciniak RA. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Cancer Gene Ther 2004, 11:691-698. 10.1038/sj.cgt.7700747, 15354201.
38. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L, Orntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD, Bartek J, Gorgoulis VG. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637. 10.1038/nature05268, 17136093.
39. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, Schurra C, Garre M, Nuciforo PG, Bensimon A, Maestro R, Pelicci PG, d'Adda di Fagagna F. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642. 10.1038/nature05327, 17136094.
40. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009, 9:400-414. 10.1038/nrc2657, 2722839, 19440234.
41. Bertos NR, Park M. Breast cancer: one term, many entities?. J Clin Invest 2011, 121:3789-3796. 10.1172/JCI57100, 3195465, 21965335.
42. Helbig G, Christopherson KW, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, Broxmeyer HE, Nakshatri H. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003, 278:21631-21638. 10.1074/jbc.M300609200, 12690099.
43. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, Massague J. Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326. 10.1016/j.cell.2009.11.025, 2810531, 20064377.
44. Russnes HG, Navin N, Hicks J, Borresen-Dale AL. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest 2011, 121:3810-3818. 10.1172/JCI57088, 3195464, 21965338.
45. Liu D, Hornsby PJ. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res 2007, 67:3117-3126. 10.1158/0008-5472.CAN-06-3452, 17409418.
46. Bhatia B, Multani AS, Patrawala L, Chen X, Calhoun-Davis T, Zhou J, Schroeder L, Schneider-Broussard R, Shen J, Pathak S, Chang S, Tang DG. Evidence that senescent human prostate epithelial cells enhance tumorigenicity: cell fusion as a potential mechanism and inhibition by p16INK4a and hTERT. Int J Cancer 2008, 122:1483-1495.
47. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci USA 2001, 98:12072-12077. 10.1073/pnas.211053698, 59769, 11593017.
48. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006, 66:605-612. 10.1158/0008-5472.CAN-05-4005, 16423985.
49. Denardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, West BL, Coussens LM. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011, 1:54-67. 10.1158/2159-8274.CD-10-0028, 3203524, 22039576.
50. Gil-Bernabe AM, Romero F, Limon-Mortes MC, Tortolero M. Protein phosphatase 2A stabilizes human securin, whose phosphorylated forms are degraded via the SCF ubiquitin ligase. Mol Cell Biol 2006, 26:4017-4027. 10.1128/MCB.01904-05, 1489102, 16705156.
51. Mora-Santos M, Limon-Mortes MC, Giraldez S, Herrero-Ruiz J, Saez C, Japon MA, Tortolero M, Romero F. Glycogen synthase kinase-3beta (GSK3beta) negatively regulates PTTG1/human securin protein stability, and GSK3beta inactivation correlates with securin accumulation in breast tumors. J Biol Chem 2011, 286:30047-30056. 10.1074/jbc.M111.232330, 21757741.
52. Molina-Jimenez F, Benedicto I, Murata M, Martin-Vilchez S, Seki T, Antonio Pintor-Toro J, Tortolero M, Moreno-Otero R, Okazaki K, Koike K, Barbero JL, Matsuzaki K, Majano PL, Lopez-Cabrera M. Expression of pituitary tumor-transforming gene 1 (PTTG1)/securin in hepatitis B virus (HBV)-associated liver diseases: evidence for an HBV X protein-mediated inhibition of PTTG1 ubiquitination and degradation. Hepatology 2010, 51:777-787. 10.1002/hep.23468, 20198633.
53. Skinner J, Bounacer A, Bond JA, Haughton MF, deMicco C, Wynford-Thomas D. Opposing effects of mutant ras oncoprotein on human fibroblast and epithelial cell proliferation: implications for models of human tumorigenesis. Oncogene 2004, 23:5994-5999. 10.1038/sj.onc.1207798, 15208687.
54. Benanti JA, Galloway DA. Normal human fibroblasts are resistant to RAS-induced senescence. Mol Cell Biol 2004, 24:2842-2852. 10.1128/MCB.24.7.2842-2852.2004, 371123, 15024073.
55. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767. 10.1016/0092-8674(90)90186-I, 2188735.
56. Hamid T, Malik MT, Kakar SS. Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells. Mol Cancer 2005, 4:3. 10.1186/1476-4598-4-3, 546418, 15649325.
57. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973, 51:1409-1416.
58. Singh S, Nannuru KC, Sadanandam A, Varney ML, Singh RK. CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer 2009, 100:1638-1646. 10.1038/sj.bjc.6605055, 2696769, 19401689.
59. Cataisson C, Ohman R, Patel G, Pearson A, Tsien M, Jay S, Wright L, Hennings H, Yuspa SH. Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis. Cancer Res 2009, 69:319-328. 10.1158/0008-5472.CAN-08-2490, 2872171, 19118017.
60. Singh S, Varney M, Singh RK. Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res 2009, 69:411-415. 10.1158/0008-5472.CAN-08-3378, 2652477, 19147552.
61. Nannuru KC, Sharma B, Varney ML, Singh RK. Role of chemokine receptor CXCR2 expression in mammary tumor growth, angiogenesis and metastasis. J Carcinogenesis 2011, 10:40.
62. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 2007, 9:493-505. 10.1038/ncb1567, 17450133.